Blinatumomab for infant acute lymphoblastic leukemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Blinatumomab for infant acute lymphoblastic leukemia

Published:2020-04-23 Issue:17 Volume:135 Page:1501-1504
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Clesham Katherine¹,Rao Vasudha¹,Bartram Jack¹,Ancliff Philip¹,Ghorashian Sara¹,O’Connor David¹²^ORCID,Pavasovic Vesna¹,Rao Anupama¹,Samarasinghe Sujith¹,Cummins Michelle³,Malone Andrea⁴,Patrick Katharine⁵,Bonney Denise⁶,James Beki⁷,Gibson Brenda⁸,Vora Ajay¹

Affiliation:

1. Great Ormond Street Hospital for Children, London, United Kingdom;

2. Department of Haematology, University College London Cancer Institute, London, United Kingdom;

3. University Hospitals Bristol, Bristol, United Kingdom;

4. Children’s Health Ireland at Crumlin, Dublin, Ireland;

5. Sheffield Children’s Hospital, Sheffield, United Kingdom;

6. Royal Manchester Children’s Hospital, Manchester, United Kingdom;

7. Leeds Children’s Hospital, Leeds, United Kingdom; and

8. Royal Hospital for Children, Glasgow, United Kingdom

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/135/17/1501/1724637/bloodbld2019004008.pdf

Reference11 articles.

1. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial;Pieters;Lancet,2007

2. Outcome of infants younger than 1 year with acute lymphoblastic leukemia treated with the Interfant-06 protocol: results from an international phase III randomized study;Pieters;J Clin Oncol,2019

3. Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol [published correction appears in Leukemia. 2017;31(12):2854];Driessen;Leukemia,2016

4. Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia;von Stackelberg;J Clin Oncol,2016

5. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia [published correction appears in Blood. 2019;133(24):2625];Gökbuget;Blood,2018

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Quality Approach to Blinatumomab Delivery in Pediatric Oncology: A Children's Oncology Group Study;Journal of Pediatric Hematology/Oncology Nursing;2024-09-08

2. Blinatumomab vs Chemotherapy for Pediatric and Adult Acute Lymphoblastic Leukemia;OBM Genetics;2024-07-19

3. Outcomes of infants with very late relapse of acute lymphoblastic leukaemia initially treated in Interfant‐06;British Journal of Haematology;2024-07-09

4. Blinatumomab in pediatric acute lymphoblastic leukemia: one center experience;Russian Journal for Personalized Medicine;2024-06-11

5. Immune escape of B-cell lymphoblastic leukemic cells through a lineage switch to acute myeloid leukemia;Leukemia & Lymphoma;2024-05-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3